Axsome Therapeutics, Inc.
NASDAQ:AXSMBiotechnology
+$0.25 today
- Market cap
- $7.05B
- Beta
- 0.60
- P/E (TTM)
- -68.6
- EPS (TTM)
- -$3.68
Volume 0.74M
Average 0.72M
AXSM Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
Axsome Therapeutics, Inc.NASDAQ: AXSM
Net Receivables · Q2 FY2026 · quarter ended Jun 2026
Net receivables rises 39.5% from a year ago
Net receivables stood at $277.46M at the end of Q2 FY2026, up 39.5% from a year earlier and up 10.5% from the prior quarter. Over 3 fiscal years it compounded at +81.2% a year.
Context
- Net receivables amounted to 36.4% of total assets at the end of Q2 FY2026, up 5.4 pp from a year earlier.
- Net receivables increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +39.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2025
- 224.46M USD
- Year-over-year change
- +58.1%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 224.46M | +58.1% |
| FY2024 | 2024-12-31 | 142M | +49.8% |
| FY2023 | 2023-12-31 | 94.82M | +151.5% |
| FY2022 | 2022-12-31 | 37.7M | — |
| FY2021 | 2021-12-31 | 0 | — |
Net Receivables vs competitors
How AXSM compares with its peers on the latest reported figures
- AXSM's Jun 2026 net receivables of $277.46M is the 3rd highest of the 11 companies compared; the peer median is $1.01M.
- Its year-over-year change of +39.5% is the 3rd highest of 6, against a peer median of +31.5%.
- Net receivables amounts to 36.4% of total assets for AXSM, versus a peer median of 0.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $957.3M | +31.5% | +25.2% | 17.0% | |
| Sep 2026 | $873.7M | +14.3% | +8.4% | 7.3% | |
| Jun 2026 | $277.46M | +39.5% | +81.2% | 36.4% | |
| Jun 2026 | $211.66M | +50.3% | +4.3% | 14.8% | |
| Jun 2026 | $3.93M | — | -38.3% | 0.3% | |
| Sep 2026 | $1.17M | +44.0% | +11.6% | 0.1% | |
| Dec 2025 | $844K | -67.0% | -36.7% | 0.6% | |
RAPPRapport Therapeutics, Inc. Common Stock | Mar 2026 | $58K | — | — | 0.0% |
| Sep 2026 | $0 | — | — | 0.0% | |
DFTXDefinium Therapeutics, Inc. | Sep 2026 | $0 | — | — | 0.0% |
NMRANeumora Therapeutics, Inc. Common Stock | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding AXSM) | $1.01M | +31.5% | +6.4% | 0.2% | |
Competitors are the stored peer set for AXSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 86.47M | 200.84M | 386.19M | 315.35M | 322.93M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 37.7M | 94.82M | 142M | 224.46M |
| Inventory | 0 | 4.32M | 15.14M | 15.73M | 27.94M |
| Other Current Assets | 0 | 2.78M | 8.12M | 11.98M | 13.65M |
| Total Current Assets | 86.52M | 245.64M | 504.26M | 485.06M | 588.99M |
| Property, Plant & Equipment (Net) | 944.01K | 1.14M | 7.62M | 5.97M | 20.86M |
| Goodwill | 0 | 10.31M | 12.04M | 12.04M | 12.04M |
| Intangible Assets | 0 | 59.66M | 53.29M | 46.89M | 40.52M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 322.91K | 14.72M | 11.03M | 18.53M | 27.4M |
| Total Non-current Assets | 1.27M | 85.83M | 83.97M | 83.43M | 100.82M |
| Total Assets | 87.79M | 331.48M | 588.24M | 568.5M | 689.81M |
| Account Payables | 13.15M | 38.61M | 40.68M | 72M | 65.54M |
| Short-term Debt | 0 | 0 | 0 | 0 | 72.98M |
| Tax Payables | 0 | 0 | 0 | 960K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 4.05M | 17.18M | 76.45M | 36.51M | 203.28M |
| Total Current Liabilities | 23.07M | 96.56M | 138.85M | 230.1M | 378.84M |
| Long-term Debt | 49.09M | 94.26M | 178.07M | 180.71M | 140.93M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 31.1M | 73.3M | 91.68M | 54.36M |
| Total Non-current Liabilities | 49.09M | 125.36M | 258.41M | 281.38M | 222.67M |
| Total Liabilities | 72.15M | 221.92M | 397.26M | 511.48M | 601.51M |
| Common Stock | 3.78K | 4K | 5K | 5K | 5K |
| Retained Earnings | (409.2M) | (596.33M) | (835.57M) | (1.12B) | (1.31B) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | (0) | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 15.63M | 109.56M | 190.98M | 57.02M | 88.3M |
| Total Debt | 49.71M | 94.68M | 186.37M | 192.96M | 241.3M |
| Net Debt | (36.76M) | (106.16M) | (199.82M) | (122.4M) | (81.64M) |
Axsome Therapeutics, Inc.
NASDAQ:AXSM
Intrinsic Alpha fair value
Locked
Current Price
$134.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.